文献速递肿瘤 PET/CT核素与放射性配体治疗

双原发恶性肿瘤患者对177Lu-PSMA与177Lu-DOTA-IBA联合治疗显著应答

Remarkable Response to 177 Lu-PSMA and 177 Lu-DOTA-IBA Cocktail Therapy in a Patient With Dual Primary Malignancies.
PubMed 文献 · Clin Nucl Med · 2026-02-09

一例转移性非典型右肺类癌患者经68Ga-FAP2286和68Ga-DOTATATE PET/CT评估显示任一示踪剂均不能覆盖全部病灶,同期发现前列腺肿物且PSA显著升高,活检确诊为伴神经内分泌分化的前列腺腺癌。68Ga-PSMA PET/CT显示全部病灶高摄取,据此给予177Lu-PSMA与177Lu-DOTA-IBA联合治疗,一周期联合治疗及一周期177Lu-DOTA-IBA治疗后两种原发恶性肿瘤及全部转移灶均接近完全缓解。

要点

  • 多模态分子影像可指导双原发肿瘤的核素治疗选择。
  • 68Ga-PSMA PET/CT显示全部病灶高摄取,支持177Lu-PSMA治疗。
  • 一周期联合治疗加一周期177Lu-DOTA-IBA后接近完全缓解。

核心结论

  • 在68Ga-PSMA PET/CT显示全部病灶高摄取的指导下,177Lu-PSMA与177Lu-DOTA-IBA联合治疗使该双原发恶性肿瘤患者两种原发肿瘤及全部转移灶接近完全缓解。

研究设计与样本

  • 本文为单例病例报告,患者为转移性非典型右肺类癌并同期确诊伴神经内分泌分化的前列腺腺癌。

主要发现

  • 68Ga-FAP2286和68Ga-DOTATATE PET/CT显示任一示踪剂均不能覆盖全部病灶。
  • 前列腺肿物伴PSA水平显著升高,活检证实为伴神经内分泌分化的前列腺腺癌。
  • 68Ga-PSMA PET/CT显示全部病灶高摄取。
  • 一周期177Lu-PSMA与177Lu-DOTA-IBA联合治疗及一周期177Lu-DOTA-IBA治疗后,两种原发恶性肿瘤及全部转移灶接近完全缓解。

临床怎么用

  • 对双原发或多原发肿瘤患者,可综合多种分子影像示踪剂评估病灶覆盖情况以指导核素治疗选择。
  • 当68Ga-PSMA PET/CT显示全部病灶高摄取时,可考虑177Lu-PSMA为基础的联合核素治疗。

局限性

  • 本文为单例病例报告,结论的普遍适用性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A patient with metastatic atypical right lung carcinoid underwent 68 Ga-FAP2286 and 68 Ga-DOTATATE PET/CT scans to assess eligibility for radionuclide therapy, which revealed insufficient coverage of all lesions by either tracer. The imaging also identified a prostate mass with markedly elevated PSA level; biopsy confirmed prostate adenocarcinoma with neuroendocrine differentiation. Subsequent 68 Ga-PSMA PET/CT demonstrated high uptake in all lesions. Guided by these multimodal imaging, the patient received combined 177 Lu-PSMA and 177 Lu-DOTA-IBA therapy. Notably, he achieved near-complete remission of both primary malignancies and all metastases after one cycle of cocktail therapy and one cycle of 177 Lu-DOTA-IBA therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tian C, Xie LB, Liu Z, et al. Remarkable Response to 177 Lu-PSMA and 177 Lu-DOTA-IBA Cocktail Therapy in a Patient With Dual Primary Malignancies. Clin Nucl Med. 2026. PMID: 41697713. doi:10.1097/RLU.0000000000006380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。